Sanofi, a 10%+ owner of Attovia Therapeutics, Inc. ($ATTO), acquired 300,000 shares of the company's stock through an open-market purchase on August 6, 2026. The transaction was executed at a price of $17.00 per share, bringing the total value of the purchase to $5.1 million. The required Form 4 filing was submitted to the Securities and Exchange Commission on August 7, 2026, one day after the trade date.
According to the SEC filing, Sanofi held 1,082,855 shares of Attovia Therapeutics following the transaction. Working backward from that post-transaction total, the 300,000-share purchase implies a pre-purchase holding of 782,855 shares. The acquisition increased Sanofi's position by approximately 38 percent relative to its prior stake in the company.
The filing was submitted under SEC accession number 0001193125-26-340173. Under Section 16(a) of the Securities Exchange Act of 1934, any person or entity that beneficially owns more than 10 percent of a registered class of a company's equity securities is required to file a Form 4 disclosing changes in that ownership position. The filing must be submitted within two business days of the transaction. The one-day interval between the August 6 trade date and the August 7 filing date was within that statutory reporting window.
The August 6 purchase was the only insider transaction recorded for $ATTO in the database. No prior Form 4 filings — whether open-market purchases, open-market sales, or equity grants — by any insider of Attovia Therapeutics were identified. Similarly, Sanofi had no other Form 4 submissions in the database at the time of the trade, making this its sole recorded filing.
A review of congressional trading disclosures found no STOCK Act filings involving $ATTO by any member of the United States House of Representatives or Senate. The ticker does not appear in any lawmaker's publicly reported trade history.
Attovia Therapeutics trades on the Nasdaq under the symbol $ATTO, and the company's SEC filings are indexed under CIK number 2058707. Sanofi, identified in the Form 4 filing under CIK 1121404, reported the transaction in its capacity as a beneficial owner holding more than 10 percent of the company's outstanding equity securities.
The transaction was a direct open-market purchase rather than a derivative conversion, option exercise, or equity grant. The Form 4 listed the transaction code "P," denoting an open-market or private purchase of securities. Open-market acquisitions by significant shareholders are subject to Section 16 reporting requirements and provide public disclosure of the trade date, size, price per share, and resulting ownership position.